加载中
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
前收盘价
US$19.90
+US$0.77 · +4.03%
盘中时间采用ET。市场数据可能有所延迟。
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
日内区间
当前US$19.90
52周区间
当前US$19.90
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
45
合理估值
情绪
48
多空交织
风险
72
高风险
动量
75
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
日内区间
当前US$19.90
52周区间
当前US$19.90
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | — | 349.2万 USD | 896万 USD | — |
| 毛利 | — | — | −349.2万 USD | −896万 USD | — |
| 研究与开发 | 3.22亿 USD | 9331万 USD | 9431.5万 USD | 6455万 USD | 4752.9万 USD |
| 销售、一般及管理费用 | 5011万 USD | 2787.5万 USD | 3172.1万 USD | 1990.8万 USD | 2148.9万 USD |
| 营业费用 | 3.72亿 USD | 1.21亿 USD | 1.23亿 USD | 8445.8万 USD | 6901.8万 USD |
| 利息收入 | 586.8万 USD | 427.1万 USD | 817.3万 USD | 132.4万 USD | 11.9万 USD |
| 折旧和摊销 | 288.7万 USD | 352.8万 USD | 349.2万 USD | 252.5万 USD | 143.4万 USD |
| 营业利润 | −3.72亿 USD | −1.21亿 USD | −1.26亿 USD | −9341.8万 USD | −6901.8万 USD |
| 净利润 | −6.96亿 USD | −1.17亿 USD | −1.18亿 USD | −9209.4万 USD | −6889.9万 USD |
公司数据更新于 2026年10月12日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$29.00
上涨空间 45.73%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3486.39万0.00%2.3万亿 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI2116.52万0.21%98.74亿 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1937.83万0.02%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1118.15万0.01%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO527.08万0.03%180亿 USD0.06%US$112.66+0.50%
Fidelity Enhanced Small Cap ETFFESM482.71万0.07%64.1亿 USD0.28%US$45.46+0.46%
iShares Russell 2000 Growth ETFIWO470.01万0.03%139.17亿 USD0.24%US$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA396.43万0.02%218.24亿 USD0.03%US$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
